Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, ...

PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical ...

Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such ...

Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a leading pharmaceutical company in Greater China, announced that they have entered into an exclusive global license ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...